Malaria Falciparum
82
5
8
60
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Research Maturity
60 completed trials (73% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.1%
5 terminated out of 82 trials
92.3%
+5.8% vs benchmark
32%
26 trials in Phase 3/4
13%
8 of 60 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 60 completed trials
Clinical Trials (82)
Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria
Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults
A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants
Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar
Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana
Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
Perennial Malaria Chemoprevention in the Malaria Vaccine Era
MDA and Targeted Control Against Plasmodium Carriage in the Sahel
Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults
IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants
Clinical Practices for Treating Severe Malaria Caused by P. Falciparum
Private Medicine Retailer-based Trial of Malaria Tests and Conditional Treatment Subsidies Among Patients With Fever
A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults
Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP
Proactive Community Case Management for Malaria in Zambia
Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria
Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam